Drugs / ATOR-1015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03782467 | Jan 2019 → Mar 2021 | neoplasm | Alligator Bioscience AB | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2020-11-09 | Alligator Bioscience AB | Results Alligator Bioscience presents at the SITC 35th Annual Meeting alligatorbioscience.se ↗
Best clinical response is stable disease. |
| 2020-09-16 | Alligator Bioscience AB | Regulatory Alligator Bioscience receives patent approval for the drug candidate ATOR-1015 alligatorbioscience.se ↗
the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,774,150 which covers compositions of matter directed to Alligator’s bispecific drug candidate ATOR-1015. |
| 2020-05-29 | Alligator Bioscience AB | Results Alligator Bioscience presents novel supportive Phase I data at ASCO for its CTLA-4 x OX40 bispecific drug candidate ATOR-1015 alligatorbioscience.se ↗
The results from the evaluation of doses up and including 600 mg (about 10 mg/kg) show that ATOR-1015 is well tolerated, and dose-escalation has continued to 750 mg (12.5 mg/kg). |
| 2020-04-27 | Alligator Bioscience AB | Results Alligator Bioscience presents promising interim Phase I data for its bispecific drug candidate ATOR-1015 at AACR alligatorbioscience.se ↗
ATOR-1015 has so far been well tolerated. |
| 2019-04-11 | Alligator Bioscience AB | Results Alligator Bioscience: Preclinical data on the tumor-localizing anti-CTLA-4 antibody ATOR-1015 published in the Journal for ImmunoTherapy of Cancer alligatorbioscience.se ↗
The published data show that ATOR-1015 localizes to the tumor with anti-tumor effects in several experimental tumor models, including bladder, colon and pancreas cancer. |
| 2019-04-10 | Alligator Bioscience AB | Results Alligator Bioscience to present new preclinical data on ATOR-1015 at PEGS Boston alligatorbioscience.se ↗
The presentation will showcase new preclinical tumor-localization data for ATOR-1015 demonstrating that ATOR-1015 physically localizes to the tumor in an experimental tumor model using a live imaging computerized technique. |
| 2018-07-19 | Alligator Bioscience AB | Regulatory Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody alligatorbioscience.se ↗
We are very pleased to announce the CTA submission and look forward to starting patient recruitment as fast as possible after regulatory approval. |
| 2018-04-17 | Alligator Bioscience AB | Results Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation alligatorbioscience.se ↗
The preclinical data demonstrate that ATOR-1015 physically localizes to the tumor and selectively activates the immune system in the tumor area, confirming the intended ATOR-1015 mechanism of action. |
| 2017-05-04 | Alligator Bioscience AB | Results Alligator Bioscience presents promising immuno-oncology data at US conference; – Strong new preclinical findings for ADC-1013 and ATOR-1015 alligatorbioscience.se ↗
The ATOR-1015 mechanism of action was confirmed in vitro and in vivo, and demonstrated tumor-directed immune activation. |
All press releases naming this drug 15 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATOR-1015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03782467 ↗ |
| Modality | Monoclonal antibody | “Bispecific human monoclonal antibody” NCT03782467 ↗ |
| Route | Intravenous | “administered as repeated intravenous infusions” NCT03782467 ↗ |